Background: PARADIGM-HF demonstrated superiority of sacubitril/valsartan (sac/val) over
enalapril in patients with heart failure with reduced ejection fraction (HFrEF). However …

This review aims to assess the benefits and adverse effects of sacubitril/valsartan in heart
failure, with a focus on important patient outcomes. A systematic review was conducted of …

Current guidelines recommend angiotensin receptor blocker neprilysin inhibitors
(ARNI)(sacubitril/valsartan) as a replacement for angiotensin-converting-enzymeinhibitor …

Sacubitril/valsartan reduces heart failure (HF)-related hospitalizations and cardiovascular
mortality in PARADIGM-HF and has become a foundational treatment for HF with reduced …

Introduction Sacubitril/valsartan has been established as an effective treatment for heart
failure (HF) with reduced ejection fraction based on clinical trial data; however, little is known …

Aims We systematically reviewed the European real‐world evidence (RWE) about sacubitril‐
valsartan for heart failure with reduced ejection fraction. Methods and results Twenty‐one …

Aims Sacubitril/valsartan significantly reduced heart failure (HF) hospitalization and
cardiovascular mortality in a randomized controlled trial. However, little is known about real …

Objectives: The aim of this study was to assess the prevalence and variation in angiotensin
receptor/neprilysin inhibitor (ARNI) prescription among a real-world population with heart …

This study aimed at analyzing the clinical profile of real-world patients with heart failure with
reduced ejection fraction (HFrEF) and evaluating the safety and efficacy of …

Current international guidelines recommend switching angiotensin converting enzyme
inhibitors (ACE-i) or angiotensin receptor blockers (ARBs) to sacubitril/valsartan (S/V) in …